These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17219666)

  • 41. Anti-HIV agents. Abacavir--as good as AZT?
    TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
    [No Abstract]   [Full Text] [Related]  

  • 42. AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
    Gallant JE
    Hopkins HIV Rep; 2003 Jul; 15(4):1-2. PubMed ID: 14696559
    [No Abstract]   [Full Text] [Related]  

  • 43. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
    Delaunay C; Brun-Vézinet F; Landman R; Collin G; Peytavin G; Trylesinski A; Flandre P; Miller M; Descamps D
    J Virol; 2005 Aug; 79(15):9572-8. PubMed ID: 16014919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
    Sax PE; Tierney C; Collier AC; Daar ES; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Feinberg J; Tashima K; Murphy RL; Fischl MA;
    J Infect Dis; 2011 Oct; 204(8):1191-201. PubMed ID: 21917892
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
    Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population.
    Gilliam BL; Sajadi MM; Amoroso A; Davis CE; Cleghorn FR; Redfield RR
    AIDS Patient Care STDS; 2007 Apr; 21(4):240-6. PubMed ID: 17461718
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
    Pammi M; Arumainayagam J; Kumari B; Ahmed-Jushuf I; Carlin EM; Chandramani S; Riddell L; Ghanem M; Das S
    Int J Clin Pract; 2013 Sep; 67(9):922-3. PubMed ID: 23952469
    [No Abstract]   [Full Text] [Related]  

  • 48. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
    Nishijima T; Komatsu H; Teruya K; Tanuma J; Tsukada K; Gatanaga H; Kikuchi Y; Oka S
    AIDS; 2013 Mar; 27(5):839-42. PubMed ID: 23719354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimizing initial therapy for HIV infection.
    Hull MW; Montaner JS
    J Infect Dis; 2011 Oct; 204(8):1154-6. PubMed ID: 21917886
    [No Abstract]   [Full Text] [Related]  

  • 50. Abacavir arm stopped in clinical trial.
    James JS
    AIDS Treat News; 2003 Apr; (390):6-7. PubMed ID: 12739475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Abandon Trizivir when it's working well? A rebuttal.
    Erbelding EJ
    Hopkins HIV Rep; 2003 Jul; 15(4):1. PubMed ID: 14696560
    [No Abstract]   [Full Text] [Related]  

  • 52. HPV oral infection. Case report of an HIV-positive Nigerian sex worker.
    Martini S; Colella G; Masiello A; Lanza A; Pisapia R; Cascone A; Di Martino F; Filippini A; Filippini P
    Infez Med; 2007 Jun; 15(2):115-8. PubMed ID: 17598999
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Viread, Epivir and Ziagen combination: failure in naïve patients with a once-daily regimen.
    Berger DS
    Posit Aware; 2003; 14(5):51-2. PubMed ID: 14679946
    [No Abstract]   [Full Text] [Related]  

  • 54. Long-term control of viral residual replication under maintenance therapy with Trizivir after a quadruple induction regimen in HIV-1-infected adults (Suburbs trial).
    de Truchis P; Mathez D; Force G; Rouveix E; Khuong MA; Chemlal K; Thiaux C; Leibowitch J
    HIV Clin Trials; 2007; 8(2):102-4. PubMed ID: 17507326
    [No Abstract]   [Full Text] [Related]  

  • 55. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
    Post FA; Moyle GJ; Stellbrink HJ; Domingo P; Podzamczer D; Fisher M; Norden AG; Cavassini M; Rieger A; Khuong-Josses MA; Branco T; Pearce HC; Givens N; Vavro C; Lim ML
    J Acquir Immune Defic Syndr; 2010 Sep; 55(1):49-57. PubMed ID: 20431394
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
    [No Abstract]   [Full Text] [Related]  

  • 57. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine.
    DeJesus E; Ruane P; McDonald C; Garcia F; Sharma S; Corales R; Ravishankar J; Khanlou H; Shamblaw D; Ecker J; Ebrahimi R; Flaherty J;
    HIV Clin Trials; 2008; 9(2):103-14. PubMed ID: 18474495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.
    Wohl DA; Arnoczy G; Fichtenbaum CJ; Campbell T; Taiwo B; Hicks C; McComsey GA; Koletar S; Sax P; Tebas P; Ha B; Massengale K; Walsh K; Stein JH
    Antivir Ther; 2014; 19(2):141-7. PubMed ID: 23985706
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [First HIV triple therapy with one tablet].
    Dtsch Med Wochenschr; 2000 Feb; 125(8):A22. PubMed ID: 10723466
    [No Abstract]   [Full Text] [Related]  

  • 60. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
    Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.